CD40 Ligand

CD40 Ligand 詳細

英語名CD40 ligand市販薬剤の数0
治験薬の数14ターゲットの別称CD154 Antigen,HCD40L,CD154,TNFSF5,CD40L,CD40 ligand, soluble form,CD40 ligand, membrane form,Tumor necrosis factor ligand superfamily member 5,T-cell antigen Gp39,CD40-L,CD40LG,TNF-Related Activation Protein,Tumor Necrosis Factor (Ligand) Superfamily Member 5,T-B Cell-Activating Molecule,T-BAM,HIGM1,Gp39,IMD3,IGM,CD40 Ligand,CD40 Antigen Ligand,TRAP,Tumor Necrosis Factor (Ligand) Superfamily, Member 5 (Hyper-IgM Syndrome),Hyper-IgM Syndrome,sCD40L
研究&開発段階Phase 3 Clinical
英語名CD40 ligand
ターゲットの別称CD154 Antigen,HCD40L,CD154,TNFSF5,CD40L,CD40 ligand, soluble form,CD40 ligand, membrane form,Tumor necrosis factor ligand superfamily member 5,T-cell antigen Gp39,CD40-L,CD40LG,TNF-Related Activation Protein,Tumor Necrosis Factor (Ligand) Superfamily Member 5,T-B Cell-Activating Molecule,T-BAM,HIGM1,Gp39,IMD3,IGM,CD40 Ligand,CD40 Antigen Ligand,TRAP,Tumor Necrosis Factor (Ligand) Superfamily, Member 5 (Hyper-IgM Syndrome),Hyper-IgM Syndrome,sCD40L
市販薬剤の数0
治験薬の数14
研究&開発段階Phase 3 Clinical

CD40 Ligandバックグランド

CD40 ligand is also known as CD40L, CD154, TNFSF5 and T-cell antigen Gp39, is a single-pass type I I membrane protein which belongs to the TNF superfamily of molecules. CD40 ligand is expressed predominantly on activated CD4+ T lymphocytes, and also found in other types of cells, including platelets, mast cells, macrophages, basophils, NK cells, B lymphocytes, as well as non-haematopoietic cells (smooth muscle cells, endothelial cells, and epithelial cells). Although all monomeric, dimeric and trimeric forms of soluble CD40 ligand can bind to CD40, the trimeric form of soluble CD40 ligand has the most potent biological activity through oligomerization of cell surface CD40, a common feature of TNF receptor family members. CD40 ligand binds to CD40 on antigen-presenting cells (APC), which leads to many effects depending on the target cell type. In general, CD40 ligand plays the role of a costimulatory molecule and induces activation in APC in association with T cell receptor stimulation by MHC molecules on the APC. In total CD40 ligand has three binding partners: CD40, α5β1 integrin and αIIbβ3. CD40 ligand regulates B cell function by engaging CD40 on the B cell surface. A defect in this gene results in an inability to undergo immunoglobulin class switch and is associated with hyper IgM syndrome.

CD40 Ligand分子の別称

CD40LG,CD154,CD40L,HIGM1,IGM,IMD3,T-BAM,TNFSF5,TRAP,gp39

治験薬に関する情報

英語名研究コード研究開発ステージ会社適応症臨床試験
Dapirolizumab pegolAnti-CD40L-Fab; Anti-CD40L-Fab-PEG; CDP-7657; CD40L - Fab; BIIB-133Phase 3 ClinicalBiogen Inc, UcbAutoimmune Diseases; Connective Tissue Diseases; Immune System Diseases; Lupus Erythematosus, Systemic; Skin and Connective Tissue Diseases
詳細
DazodalibepVIB-4920; MEDI-4920; HZN-4920(Horizon Therapeutics); UNII-HN5US76BWF; WHO-11399Phase 3 ClinicalHorizon Therapeutics PLC, Medimmune LlcArthritis, Rheumatoid; Graft Rejection; Lupus Nephritis; Rejection of renal transplantation; Sjogren's Syndrome; Sjogren-Larsson Syndrome
詳細
FrexalimabINX-021; SAR-441344Phase 3 ClinicalImmunext IncDiabetes Mellitus, Type 1; Glomerulonephritis; Glomerulosclerosis, Focal Segmental; Lupus Erythematosus, Systemic; Multiple Sclerosis; Nephrosis; Rejection of renal transplantation; Sjogren's Syndrome; Sjogren-Larsson Syndrome
詳細
Anti-CD40L antibody (Bristol-Myers Squibb)Phase 2 ClinicalBristol-Myers Squibb CompanyImmunologic Deficiency Syndromes
詳細
TegoprubartAT-1501Phase 2 ClinicalAls Therapy Development InstituteAmyotrophic Lateral Sclerosis; Diabetes Mellitus, Type 1; Glomerulonephritis, IGA; Rejection of renal transplantation
詳細
Delolimogene mupadenorepvecLOAd-703Phase 2 ClinicalLokon Pharma, Uppsala UniversityBiliary Tract Neoplasms; Colorectal Neoplasms; Melanoma; Ovarian Neoplasms; Pancreatic Neoplasms
詳細
TNX-1500TNX-1500Phase 2 ClinicalTonix Pharmaceuticals Holding CorpAutoimmune Diseases; Autoimmune Diseases of the Nervous System; Rejection of renal transplantation; Rejection of organ transplantation
詳細
Base-edited hematopoietic stem and progenitor cells therapy (NIAID)Phase 2 ClinicalNational Institute Of Allergy And Infectious Diseases (Niaid)Hyper-IgM Immunodeficiency Syndrome, Type 1
詳細
CD40 ligand expressing MSLN-CAR T cellsPhase 2 ClinicalPla General HospitalSolid tumours
詳細
LetolizumabBMS-986004; BMS2h-572-633-CT-L2Phase 1 ClinicalBristol-Myers Squibb CompanyGraft vs Host Disease; Purpura, Thrombocytopenic, Idiopathic
詳細
MEM-288MEM-288Phase 1 ClinicalMemgenCarcinoma, Merkel Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Head and Neck Neoplasms; Melanoma; Neoplasm Metastasis; Neoplasms; Pancreatic Neoplasms; Solid tumours; Triple Negative Breast Neoplasms
詳細
IBI355IBI-355Phase 1 ClinicalLupus Erythematosus, Systemic; Sjogren's Syndrome
詳細
CD40L-augmented Tumor Infiltrating Lymphocytes (H Lee Moffitt Cancer Center & Research Institute)Phase 1 ClinicalH Lee Moffitt Cancer Center & Research InstituteCarcinoma, Non-Small-Cell Lung
詳細
Lu-AG22515APB-A1; Lu-AG22515Phase 1 ClinicalAprilBio Co LtdGraves Ophthalmopathy; Neuromyelitis Optica
詳細
  • 詳細
  • 製品リスト
  • 治験薬に関する情報
お問い合わせ

お問い合わせ
グローバル:+1 800-810-0816(Toll Free)

メールアドレス
order.jp@acrobiosystems.com

アクロバイオシステムズ株式会社
〒101-0051
東京都千代田区神田神保町1-32-8